HHS awards $56.7M R&D contract to MAPP BIOPHARMACEUTICAL for life sciences research
Contract Overview
Contract Amount: $56,704,950 ($56.7M)
Contractor: Mapp Biopharmaceutical, Inc.
Awarding Agency: Department of Health and Human Services
Start Date: 2018-09-25
End Date: 2024-12-31
Contract Duration: 2,289 days
Daily Burn Rate: $24.8K/day
Competition Type: FULL AND OPEN COMPETITION
Number of Offers Received: 1
Pricing Type: COST PLUS FIXED FEE
Sector: R&D
Official Description: IGF::OT::IGF
Place of Performance
Location: SAN DIEGO, SAN DIEGO County, CALIFORNIA, 92121
Plain-Language Summary
Department of Health and Human Services obligated $56.7 million to MAPP BIOPHARMACEUTICAL, INC. for work described as: IGF::OT::IGF Key points: 1. Contract awarded to MAPP BIOPHARMACEUTICAL, INC. for research and development. 2. Full and open competition was utilized for this definitive contract. 3. The contract has a duration of 2289 days, ending in December 2024. 4. The primary sector is Research and Development in Physical, Engineering, and Life Sciences.
Value Assessment
Rating: questionable
The contract type is Cost Plus Fixed Fee, which can lead to cost overruns if not managed carefully. Benchmarking is difficult without specific cost breakdowns.
Cost Per Unit: N/A
Competition Analysis
Competition Level: full-and-open
Full and open competition was used, suggesting a competitive bidding process. However, the Cost Plus Fixed Fee structure may not always yield the lowest price.
Taxpayer Impact: Taxpayer funds are being used for R&D, with the ultimate value dependent on the success of the research outcomes.
Public Impact
Supports critical research and development in life sciences. Contract duration extends over several years, indicating a long-term project. Awarded by the Department of Health and Human Services, focusing on preparedness and response.
Waste & Efficiency Indicators
Waste Risk Score: 50 / 10
Warning Flags
- Cost Plus Fixed Fee contract type can be less price-efficient.
- Long contract duration may increase risk of scope creep or changing requirements.
Positive Signals
- Full and open competition utilized.
- Supports important R&D for public health preparedness.
Sector Analysis
This contract falls under the Research and Development in the Physical, Engineering, and Life Sciences sector. Spending in this area is crucial for innovation but can be highly variable in terms of return on investment.
Small Business Impact
The data does not indicate if small businesses were involved as subcontractors or partners in this contract.
Oversight & Accountability
Oversight is crucial for Cost Plus Fixed Fee contracts to ensure funds are used efficiently and research objectives are met. The duration necessitates ongoing monitoring.
Related Government Programs
- Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Department of Health and Human Services Contracting
- Office of Assistant Secretary for Preparedness and Response Programs
Risk Flags
- Cost Plus Fixed Fee contract type
- Long contract duration
- Uncertainty of R&D outcomes
- Potential for cost overruns
Tags
research-and-development-in-the-physical, department-of-health-and-human-services, ca, definitive-contract, 10m-plus
Frequently Asked Questions
What is this federal contract paying for?
Department of Health and Human Services awarded $56.7 million to MAPP BIOPHARMACEUTICAL, INC.. IGF::OT::IGF
Who is the contractor on this award?
The obligated recipient is MAPP BIOPHARMACEUTICAL, INC..
Which agency awarded this contract?
Awarding agency: Department of Health and Human Services (Office of Assistant Secretary for Preparedness and Response).
What is the total obligated amount?
The obligated amount is $56.7 million.
What is the period of performance?
Start: 2018-09-25. End: 2024-12-31.
What are the specific research objectives and expected outcomes of this contract?
The specific research objectives are not detailed in the provided data. However, given the awarding agency (ASPR), the research likely pertains to biopharmaceutical development for public health emergencies or preparedness. Expected outcomes would be advancements in medical countermeasures, vaccines, or treatments, contributing to national health security.
How will the effectiveness of the R&D be measured and ensured?
Effectiveness will likely be measured through milestone achievements, scientific validation of research findings, and the potential for translation into practical applications. The ASPR would establish specific performance metrics and require regular progress reports. Independent scientific review boards may also be involved to ensure research quality and adherence to scientific standards.
What is the potential return on investment for taxpayers given the R&D nature of the contract?
The return on investment for R&D contracts is inherently uncertain and long-term. Success could lead to significant public health benefits, cost savings in future crisis response, and potentially commercialization opportunities. However, there's also a risk that the research may not yield the desired results, representing a sunk cost for taxpayers.
Industry Classification
NAICS: Professional, Scientific, and Technical Services › Scientific Research and Development Services › Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Product/Service Code: RESEARCH AND DEVELOPMENT › N – Health R&D Services
Competition & Pricing
Extent Competed: FULL AND OPEN COMPETITION
Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE
Offers Received: 1
Pricing Type: COST PLUS FIXED FEE (U)
Evaluated Preference: NONE
Contractor Details
Address: 6160 LUSK BLVD STE 105, SAN DIEGO, CA, 92121
Business Categories: Category Business, Corporate Entity Not Tax Exempt, Small Business, Special Designations, Subchapter S Corporation, U.S.-Owned Business
Financial Breakdown
Contract Ceiling: $62,511,942
Exercised Options: $56,704,950
Current Obligation: $56,704,950
Actual Outlays: $26,772,410
Contract Characteristics
Commercial Item: COMMERCIAL PRODUCTS/SERVICES PROCEDURES NOT USED
Cost or Pricing Data: YES
Timeline
Start Date: 2018-09-25
Current End Date: 2024-12-31
Potential End Date: 2024-12-31 00:00:00
Last Modified: 2025-04-17
More Contracts from Mapp Biopharmaceutical, Inc.
- Procurement of Therapeutics for Ebola, Sudan and Marburg Viruses — $184.8M (Department of Health and Human Services)
- This Cost-Plus-Fixed-Fee Contract With Mapp Biopharmaceutical, Inc. (mapp or Contractor) IS for the Development of Mapp?s Therapeutic Intervention MBP091, AS an Immunotherapy for the Treatment of Marburg Virus Infection — $110.9M (Department of Health and Human Services)
- Federal Contract — $65.8M (Department of Health and Human Services)
- FOR Other Functions Advanced Development of Zmapp, an Ebola Virus Candidate Medical Countermeasure — $52.4M (Department of Health and Human Services)
- Mapp EAP - Igf::cl::igf for Other Functionsexpanded Access Protocol for Zmapp — $28.9M (Department of Health and Human Services)
Other Department of Health and Human Services Contracts
- Contact Center Operations (CCO) — $5.5B (Maximus Federal Services, Inc.)
- TAS::75 0849::TAS Oper of Govt R&D Goco Facilities — $4.8B (Leidos Biomedical Research Inc)
- THE Purpose of This Contract IS to Provide the Full Complement of Services Necessary to Care for UC in ORR Custody Including Facilities Set-Up, Maintenance, and Support Internal and Perimeter (IF Applicable) Security, Direct Care and Supervision Inc — $3.5B (Rapid Deployment Inc)
- Contact Center Operations — $2.6B (Maximus Federal Services, Inc.)
- Federal Contract — $2.4B (Leidos Biomedical Research Inc)
View all Department of Health and Human Services contracts →